Outcomes of Novel Hormonal Therapies in Men With Advanced Prostate Cancer by Treating Specialist.

ABSTRACT:

Introduction

In the past decade, the management of advanced prostate cancer has shifted to novel hormonal therapies. As a result, urologists have increased their involvement in the management of advanced prostate cancer. These therapies require close monitoring due to the possibility of adverse cardiometabolic events. We assessed outcomes among men diagnosed with advanced prostate cancer started on novel hormonal therapy by a urologist compared to those by a medical oncologist.

Methods

We performed a retrospective cohort study of Medicare beneficiaries with advanced prostate cancer treated with a novel hormonal therapy between 2012 and 2019. The primary outcome was an adverse event comprised of a hospital visit for a cardiometabolic event within 6 months of starting a novel

SUBMITTER: Faraj KS 

PROVIDER: S-EPMC12417965 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature